Dataset | Source | Tissue | Cancer type level1 | Cancer type level2 | Drug type | Regimen | Timepoint | Cell type | avg_log2FC | p_val_adj |
GSE163836 | FCIBC02 cell line | Cell line | Breast cancer | Inflammatory breast cancer | Chemotherapy | paclitaxel | NA | Malignant cells | -0.603253 | 0.00e+00 |
GSE153697 | patients | Bone marrow aspirate | Acute lymphoblastic leukemia | Relapsed B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | anti-CD19 CAR-T | NA | Malignant cells | 0.393832 | 8.00e-21 |
GSE153697 | patients | Bone marrow aspirate | Acute lymphoblastic leukemia | Relapsed B-cell acute lymphoblastic leukemia (B-ALL) | Immunotherapy | anti-CD19 CAR-T | NA | Mono/Macro | 0.461427 | 1.56e-06 |
GSE189460 | patients | Bone marrow aspirate | Multiple myeloma | Multiple myeloma (MM) | Targeted therapy | bortezomib + melphalan + prednisolone | pre | Malignant cells | 0.582527 | 0.00e+00 |
GSE139386 | H3122 cell line | Cell line | Lung cancer | EML4-ALK fusion-positive non-small cell lung cancer (NSCLC) | Targeted therapy | ceritinib | NA | Malignant cells | -0.85358 | 0.00e+00 |
GSE158457 | PDX cells | Cell line | Acute lymphoblastic leukemia | T-cell acute lymphoblastic leukemia (ALL) | Targeted therapy | dasatinib | NA | Malignant cells | -0.259258 | 0.00e+00 |
GSE199333 | patients | Bone marrow aspirate | Acute myeloid leukemia | Primary FLT3-ITD-mutated acute myeloid leukemia (AML) | Targeted therapy | gilteritinib | pre | Erythrocytes | 0.316731 | 3.12e-09 |
GSE131984_JQ1Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | JQ1 + palbociclib | NA | Malignant cells | -0.372511 | 8.59e-24 |
GSE104987 | MCF7 cell line | Cell line | Breast cancer | ER+ breast cancer | Targeted therapy | KDM5-C70 | NA | Malignant cells | -0.268956 | 9.03e-15 |
GSE131984_Pal | SUM159 cell line | Cell line | Breast cancer | Triple-negative breast cancer (TNBC) | Targeted therapy | palbociclib | NA | Malignant cells | -0.382302 | 8.33e-19 |
GSE108397 | 451Lu cell line | Cell line | Melanoma | Melanoma | Targeted therapy | PLX-4720 | NA | Malignant cells | -0.331775 | 0.00e+00 |
GSE161801_IMiD | patients | Bone marrow aspirate | Multiple myeloma | Refractory multiple myeloma (MM) | Targeted therapy | pomalidomide + dexamethasone OR lenalidomide + dexamethasone | pre | Malignant cells | -0.390319 | 0.00e+00 |
GSE164897_Vem | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib | NA | Malignant cells | 0.275625 | 0.00e+00 |
GSE164897_VemCob | A375 cell line | Cell line | Melanoma | BRAFV600E-mutant melanoma | Targeted therapy | vemurafenib + combimetinib | NA | Malignant cells | 0.348485 | 0.00e+00 |
Gene symbol | motif | TF_highConf |
TMEM106C | metacluster_111.6 | GMEB1; GMEB2 (directAnnotation). |
TMEM106C | taipale_tf_pairs__HOXD12_ETV1_RSCGGAAGTAATAAAN_CAP | ETV1; HOXD12 (directAnnotation). |
TMEM106C | taipale_tf_pairs__HOXD12_ELK1_RSCGGAAGTAATAAAN_CAP | ELK1; HOXD12 (directAnnotation). |
TMEM106C | jaspar__MA1937.1 | HOXB13 (directAnnotation). |
TMEM106C | taipale_tf_pairs__ETV2_HOXB13_NCCGGAAGTYRTAAAN_CAP | ETV2; HOXB13 (directAnnotation). |
TMEM106C | transfac_pro__M05821 | ZNF880 (directAnnotation). |
TMEM106C | transfac_pro__M05941 | ZNF471 (directAnnotation). |
TMEM106C | taipale_tf_pairs__ETV5_HOXB13_NNCGGANGNNNTWAA_CAP | ETV5; HOXB13 (directAnnotation). |
TMEM106C | jaspar__MA1936.1 | FOXO1 (inferredBy_Orthology). |
TMEM106C | taipale_tf_pairs__HOXB13_ELK1_RSMGGAARTNNTAAAN_CAP | ELK1; HOXB13 (directAnnotation). |
TMEM106C | metacluster_156.3 | DBP; DBP; DBP; DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; NFIL3; TEF; TEF; TEF; TEF; TEF (directAnnotation). DBP; DBP; DBP; DBP; DBP; HLF; HLF; HLF; HLF; HLF; NFIL3; NFIL3; NFILZ; NFILZ; TEF; TEF; TEF; TEF (inferredBy_Orthology). |
TMEM106C | metacluster_160.13 | ZNF680 (directAnnotation). |
TMEM106C | taipale_tf_pairs__HOXD12_ETV4_RSCGGAAGTAATAAAN_CAP | ETV4; HOXD12 (directAnnotation). |
TMEM106C | taipale_tf_pairs__HOXB13_ETV1_RSCGGAARYNNTAAAN_CAP_repr | ETV1; HOXB13 (directAnnotation). |
TMEM106C | transfac_pro__M06721 | ZKSCAN7 (directAnnotation). |
TMEM106C | transfac_pro__M05636 | ZNF134; ZNF154; ZNF256; ZNF304; ZNF418; ZNF419; ZNF480; ZNF548; ZNF549; ZNF552; ZNF561; ZNF562; ZNF584; ZNF586; ZNF587B; ZNF610; ZNF772; ZNF773; ZNF792; ZNF793; ZNF837 (inferredBy_Orthology). |
TMEM106C | taipale_tf_pairs__RORB_AWNTAGGTCATGACCTANWT_HT | RORB (directAnnotation). |
TMEM106C | homer__GTCACGCTCNCTGA_PAX5 | PAX5 (directAnnotation). |
TMEM106C | taipale_tf_pairs__FLI1_HOXB13_NCCGGAANTNRTAAAN_HT | FLI1; HOXB13 (directAnnotation). |
TMEM106C | metacluster_9.13 | LHX8 (directAnnotation). |
TMEM106C | metacluster_126.1 | ZNF549; ZNF549; ZNF549 (directAnnotation). |
TMEM106C | transfac_pro__M04855 | IRF4 (directAnnotation). |
TMEM106C | tfdimers__MD00061 | E2F1; NR3C1 (directAnnotation). |
TMEM106C | metacluster_161.2 | LHX8 (directAnnotation). |
TMEM106C | metacluster_161.4 | LHX9 (directAnnotation). |
TMEM106C | taipale_tf_pairs__ETV2_HOXA2_NCCGGAAGTMATTA_CAP_repr | ETV2; HOXA2 (directAnnotation). |
TMEM106C | metacluster_141.2 | E2F2; E2F3 (directAnnotation). |
TMEM106C | taipale_tf_pairs__ETV2_DRGX_RSCGGAWRYATTA_CAP_repr | DRGX; ETV2 (directAnnotation). |
TMEM106C | transfac_pro__M06331 | ZNF343 (directAnnotation). |
TMEM106C | jaspar__MA1932.1 | HOXB13 (directAnnotation). |
TMEM106C | taipale_tf_pairs__ETV5_HOXA13_NNCGGAWGTNRTWAA_CAP | ETV5; HOXA13 (directAnnotation). |
TMEM106C | metacluster_102.2 | ZBED1 (directAnnotation). |
TMEM106C | taipale_cyt_meth__SMAD5_YGTCTAGACA_eDBD_meth_repr | SMAD5 (directAnnotation). |
TMEM106C | metacluster_91.2 | SMAD3; SMAD5 (directAnnotation). |
TMEM106C | hdpi__MLX | MLX (directAnnotation). |
TMEM106C | homer__TACGTGCV_HIF-1a | HIF1A (directAnnotation). |
TMEM106C | tfdimers__MD00456 | E2F6; OVOL2 (directAnnotation). |
TMEM106C | metacluster_22.12 | NFE2; NFE2L1 (directAnnotation). |
TMEM106C | transfac_pro__M05711 | ZNF37A (directAnnotation). |
1 | "Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618." |
2 | "Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335." |